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The small molecule metal ion chelators bipyridine and ter-
pyridine complexedwithZn2 (ZnBip andZnTerp) act as CCR5
agonists and strong positive allosteric modulators of CCL3
binding to CCR5, weak modulators of CCL4 binding, and com-
petitors for CCL5 binding. Here we describe their binding site
using computational modeling, binding, and functional studies
on WT and mutated CCR5. The metal ion Zn2 is anchored
to the chemokine receptor-conserved Glu-283VII:06/7.39. Both
chelators interact with aromatic residues in the transmembrane
receptor domain. The additional pyridine ring of ZnTerp binds
deeply in the major binding pocket and, in contrast to ZnBip,
interacts directly with the Trp-248VI:13/6.48 microswitch, con-
tributing to its 8-fold higher potency. The impact of Trp-248
was further confirmed by ZnClTerp, a chloro-substituted ver-
sion of ZnTerp that showed no inherent agonism but main-
tainedpositive allostericmodulation ofCCL3binding.Despite a
similar overall bindingmodeof all threemetal ion chelator com-
plexes, the pyridine ring of ZnClTerp blocks the conformational
switch of Trp-248 required for receptor activation, thereby
explaining its lack of activity. Importantly, ZnClTerp becomes
agonist to the same extent as ZnTerp upon Ala mutation of Ile-
116III:16/3.40, a residue that constrains the Trp-248 microswitch
in its inactive conformation. Binding studies with 125I-CCL3
revealed an allosteric interface between the chemokine and the
small molecule binding site, including residues Tyr-37I:07/1.39,
Trp-86II:20/2.60, and Phe-109III:09/3.33. The small molecules and
CCL3 approach this interface from opposite directions, with
some residues being mutually exploited. This study provides
new insight into the molecular mechanism of CCR5 activation
and paves the way for future allosteric drugs for chemokine
receptors.
CCR5 is one of 19 human chemokine receptors and thereby
belongs to the protein family of seven-transmembrane helix
(7TM)2 G protein-coupled receptors (GPCRs). The human
chemokine system additionally comprises around 50 endoge-
nous chemokine ligands, which together with their receptors
organize leukocyte trafficking. A chemokine receptor can have
several chemokine ligands, and a single chemokine can bind to
several receptors, properties that confer redundancy to the sys-
tem (1). At the same time, the system’s components are spa-
tially and temporally organized and characterized by receptor,
ligand, and tissue bias (2, 3), implying that a chemokine inter-
acting with a given receptor in a certain tissue in fact relays a
very specific andnon-redundant signal (4).Thechemokine system
is investigated as a target for treating acute and chronic inflamma-
tions, allergies, and autoimmune diseases but also for cancer
growth andmetastasis, angiogenesis, and HIV infection (5).
Chemokines are 8–12-kDa large peptides that are divided
into four groups according to the position of conserved cys-
teines: CC-chemokines (25 members), CXC-chemokine (18
members), XC-chemokines (XCL1 and XCL2), and CX3CL1
(1). These cysteines form disulfide bridges with cysteines in the
chemokine core domain, which itself consists of an N-loop, a
three-stranded -sheet, and a C-terminal -helix. The N-ter-
minal residues in front of the first cysteine thereby remain
unstructured and flexible (6). Recently, two crystal structures of
chemokine receptors in complex with a chemokine ligand were
revealed: CXCR4 in complex with the viral chemokine vMIP-II
(7) and the viral chemokine receptor US28 in complex with
CX3CL1 (8). These structures confirmed the overall binding
mode of chemokines to their receptors, whereby the chemo-
kine core interacts with extracellular receptor domains, such as
the receptor N terminus and extracellular loop (ECL) 2,
whereas the flexible chemokine N terminus protrudes into the
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transmembrane receptor area. This agrees with the suggested
“pseudo”-two-step model that roughly separates the chemo-
kine-receptor interaction into an affinity-providing step 1
(chemokine core-extracellular receptor domains) and an acti-
vation-inducing step 2 (chemokine N terminus-transmem-
brane receptor domain) (9, 10).
Furthermore, crystal structures of chemokine receptors with
various ligands have been solved and show different binding
sites for each ligand. In CXCR4, the small molecule antagonist
IT1t binds to a site in the minor binding pocket (delimited by
TM-1 to -3 and -7 (11)), whereas the peptide-based CVX15
binds in the major binding pocket (delimited by TM-3 to -7)
(12). Maraviroc in CCR5 spans the major and minor binding
pockets (13), as suggested for many other small molecule CC-
chemokine receptor antagonists (14).
A comparison of the binding modes of small molecules and
chemokines shows that an overlap in binding sites may arise
within the transmembrane receptor domain, which is targeted
by the chemokine N termini and the small molecule ligands to
varying extents. Thus, although small molecules traditionally
are considered to bind allosterically to the larger orthosteric
chemokine ligands (15), they might in fact overlap with the
chemokine N terminus. A chemokine-dependent allosteric
behavior of small molecules has, for example, been shown in
CCR1. There, the binding of CCL3 was enhanced by the small
molecule agonists metal ion chelator complexes, highlighting
an allosteric bindingmode, whereas another chemokine, CCL5,
was displaced with equimolar affinities (16). CCL5 and the
metal ion chelator complexes were affected by the same trans-
membrane receptor mutations, pointing to an overlap in bind-
ing sites that results in the observed competitive binding pat-
tern for CCL5 and the small molecules. It has furthermore been
discussed whether an allosteric binding mode should be pur-
sued in the development of chemokine receptor antagonists. In
general, although allosteric binding allows for the modulation
of a chemokine-mediated response, and thereby depends on
the presence and level of the chemokine, it might not confer
strong enough antagonism to reach clinical efficacy (15, 17).
More knowledge about themolecular pharmacology of chemo-
kine receptors and their signaling outcomes under healthy and
pathological conditions is therefore needed to design ligand-
and receptor-specific or broad inhibitors or allosteric modula-
tors with distinct signaling properties.
CCR5 gained prominence as an HIV co-receptor after it was
found that the deletion variant CCR532 provides resistance to
HIV infection by abrogating normal receptor expression in
homo- and heterozygotes (18–20). This has initiated strong
drug developmental efforts, resulting in themarketing ofmara-
viroc as a CCR5 antagonist and HIV entry inhibitor in 2007
(17). Here we investigate the binding mode of agonistic allos-
teric modulators to CCR5. We have previously described the
metal ion chelator complex ZnBip (Zn2 in complex with 2,2-
bipyridine) as a small molecule agonist and allosteric enhancer
of CCL3 binding to CCR5 (and CCR1) but a competitor for
CCL5 binding (16, 21). By screening 20 chelator analogs, we
identified ZnTerp (Zn2 in complex with 2,2:6,2-terpyri-
dine), which acts more strongly than ZnBip in both agonistic
activity and allosteric modulation, and ZnClTerp (Zn2 in
complex with 4-chloro-2,2:6,2-terpyridine), which was a
pure allosteric enhancer of CCL3 binding but did not activate
CCR5 (22).We also investigate the structural basis for agonistic
and allosteric properties in CCR5.We use computational mod-
eling to predict the binding sites of the metal ion chelator com-
plexes and confirm these in vitro by receptor activation and
125I-CCL3 binding assays in 23 receptor mutants. We thereby
describe the molecular mechanism for small molecule-medi-
ated activation and allosteric modulation in CCR5.
Results
Activity of Metal Ion Chelator Complexes—As shown previ-
ously, ZnTerp is a very efficacious agonist at CCR5 with a
higher potency than ZnBip when measuring inositol 1,4,5-tris-
phosphate (IP3) formation in transiently transfected COS-7
cells expressing CCR5 and the chimeric G protein G6qi4myr
(Gqi4myr) that translates a Gi coupling to aGq readout (Fig. 1,
A and B, and Table 1) (22). As expected, the agonistic activity of
bothmetal ion chelator complexes depends on complex forma-
tion between the chelator and Zn2. To test the ligands’ ability
to induce Gi activation more directly (in the absence of the
chimeric G protein), we measured cAMP production in CHO
cells stably transfected with CCR5 (Fig. 1, D–F), which were
induced to produce cAMP with forskolin. The chemokines
CCL3 and CCL5 inhibited forskolin-induced cAMP produc-
tion (i.e. they induced Gi activation and inhibition of adenylyl
cyclase) (Fig. 1D). Also, ZnBip acted as an agonist through this
pathwaywith a potency of 4.6M (Fig. 1E); the level of this activity
depended on complex formation between Bip and Zn2 (Fig. 1F).
Similarly, we observed a specific activity of CCL3, CCL5, and
ZnBip in a Ca2-imaging assay in the same cells (Fig. 1,G–I).
Allosteric Properties of Metal Ion Chelator Complexes—Like
ZnBip, ZnTerp was previously shown to act as an allosteric
enhancer of CCL3 binding to CCR5 with an affinity (Ki) higher
than that of ZnBip (Fig. 1C) (22). A third high affinity ligand
exists for CCR5, namely CCL4, which is more closely related to
CCL3 than to CCL5. Homologous competition binding exper-
iments revealed a KD of 1.4 nM for CCL4 (Fig. 2, A and B), and
consistent with the closer structural homology between CCL3
and CCL4, CCL3 displaced 125I-CCL4 with high affinity (Ki of
3.7 nM (i.e. very similar to the Kd of 4.5 nM; see Table 2)),
whereas CCL5 was not able to displace CCL4 with high affinity
(Ki of 0.13 M) (Fig. 2C). None of the metal ion chelator com-
plexes enhanced the binding of 125I-CCL4 (Fig. 2, D–F) to the
same extent as the binding of 125I-CCL3 (Fig. 1C). In fact, they
acted oppositely, withweak displacement for ZnBip (Ki value of
290M) andweak enhanced binding forZnTerp,with aKiof 1.8
M and maximal enhancement of 160% (compared with 670%
for CCL3) (Fig. 2, D and E, respectively). Thus, consistent with
previous observations (16, 21), this shows that the allosteric
property of metal ion chelators is chemokine-dependent.
Computational Modeling—We decided to explore the bind-
ing sites of ZnBip and ZnTerp in CCR5. Due to their agonistic
nature, we built an active-like CCR5 model in MODELLER
using the crystal structure of the constitutively active chemo-
kine receptor US28 (PDB entry 4XT1) (Fig. 3, A–C). In com-
parison with the inactive CCR5 crystal structure in complex
with maraviroc (PDB entry 4MBS), our model shows confor-
Allosteric Modulation and Agonism in CCR5
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mational changes and active-like characteristics; the extracel-
lular part of TM-1 ismoved slightly toward TM-7, the extracel-
lular part of TM-2 is slightly tilted away from TM-1, ECL-1 is
tilted further outward, ECL-3 is tilted further inward, andmost
characteristically for the active-like conformation, the intracel-
lular part of TM-6 is tilted away from the center of the TM-
bundle (Fig. 3, A and B). Furthermore, all binding pocket
residues are slightly altered in their position, and a tighter
aromatic interaction is observed between Tyr-108III:08/3.32,
Phe-109III:09/3.33, and Phe-112III:12/3.36 in TM-3. Furthermore,
the side chains of Tyr-244VI:09/6.44, Trp-248VI:13/6.48, and Tyr-
251VI:16/6.51 in TM-6 are rotated slightly downward toward the
intracellular receptor side (Fig. 3C) (the residue position
according to the Baldwin-Schwartz and Ballesteros-Weinstein
numbering system is given in superscript the first time a residue
is mentioned (23, 24)).
The chelators were then docked to a model in which the
suggested metal ion anchor Glu-283VII:06/7.39 (16, 21, 22) has
been manually set to coordinate a Zn2 ion. A water mole-
cule is positioned in the minor binding pocket and bridges
Tyr-37I:08/1.39, Tyr-108, Glu-283, and the Zn2 ion. Both Bip
and Terp dock to the same area and largely overlap in their
binding sites. Importantly, the major binding pocket of
CCR5 becomes very narrow between Tyr-108, Phe-109, and
Tyr-251 before extending to a small lower cavity bordered by
Phe-112 and Trp-248. The additional pyridine ring of Terp
protrudes into this lower cavity of the major binding pocket
(Fig. 3D).
Both Bip and Terp make van der Waals contacts with Tyr-
108, Phe-109, and Tyr-251 in the major binding pocket, -
stacking with Tyr-37 and Trp-86II:20/2.60 in the minor binding
pocket, and cation- interactions with Arg-168Cys-10 in ECL-
2a. Terp additionally interacts with Phe-112 and Trp-248 deep
in the major binding pocket (Fig. 3, D–F).
Probing the CCR5-bound Zn2-Terp Complex—The model-
ing suggested two alternative poses for Terp in CCR5, one with
FIGURE 1. A, structures of ZnBip and ZnTerp; B, activity of ZnBip (black circle) and ZnTerp (black square) at CCR5 asmeasured in an IP3 assay (see “Experimental
Procedures” for details). Non-complexed controls are shown in white (Zn2, Terp, and Bip shown as circles, squares, and diamonds, respectively). Data are
normalized to maximal response induced by chemokine at CCR5 (n  3). C, ability of ZnBip and ZnTerp to enhance the binding of 125I-CCL3 to CCR5, as
determined in a heterologous competition binding assay. Data are normalized to the homologous binding curve (n  3). For B and C, see Table 1 and 3,
respectively. D–F, cAMP turnover experiments in stably transfected CHO cells representing inhibition of adenylyl cyclase in response to Gi activation. D,
activity of 0.1 M CCL3 and CCL5 in untransfected cells (controls) and stably transfected CCR5-expressing cells. *, p  0.1; **, p  0.01 as calculated by the
Mann-Whitney test (t test for unpaired non-parametric data). E, specific normalized cAMP turnover induced by ZnBip in CCR5-expressing cells (background
subtracted); 100% represents the lowest observed level of cAMP in the absence of forskolin stimulation, and 0% is the initial cAMP level in the assay induced
by 10 M forskolin (see “Experimental Procedures” for details). D and E, n  3. F, direct readout from one representative cAMP turnover assay of three
experiments for ZnBip, Zn2, and Bip in CCR5-CHO cells (arbitrary units). G and H, fluorescence-based Ca2 assays in stably transfected CHO cells; one
representative experiment of three is shown. The arrow indicates when ligandswere added (at 80 s). Shown is the activity of 0.1MCCL3 and CCL5 (G) or 1mM
ZnBip (H) in untransfected cells and stably transfected CCR5-expressing cells. I, activity of 1 mM ZnBip in comparison with 1 mM Zn2 and 1 mM Bip alone in
stably transfected CCR5-expressing cells.
Allosteric Modulation and Agonism in CCR5
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all three nitrogen atoms coordinated to Zn2 and another with
pyridyl in the lower cavity rotated away from Zn2. This
prompted us to investigate the need for a tridentate interaction.
To this end, Terp analogues were synthesizedwith the terminal
pyridyl shifted to the meta- (mTerp) or para-position (pTerp)
(25, 26) or replaced by phenyl (PhBip) (27, 28) (Fig. 4). Thus, all
analogueswereunable to formatridentatecomplexwithZn2but
otherwise as closely as possible preserved the features of Terp.
TABLE 1
Activation of CCR5 andmutant receptors by CCL3, CCL5, ZnBip and ZnTerp
The name and position ofmutants according to the Ballesteros/Weinstein (left) and Baldwin/Schwartz numbering system are given. The surface expression of eachmutant
was determined by ELISAusingN-terminally Flag-tagged receptors. The activity of ligandswasmeasured in an IP3 assay inCOS-7 cells co-transfectedwith the receptor and
the promiscuous G protein Gqi4myr. EC50 (activity) values are given in log and nM/M. Fmut is the factor presenting the -fold decrease of EC50 for the mutant compared to
WT CCR5. The number of experiments (n) is given in parantheses.
FIGURE 2. Homo- and heterologous competition binding assays with 125I-CCL4. A, average of original CCL4 binding data in cpm; binding to COS-7 cells
transiently transfectedwithCCR5 (drawn line) or untransfectedCOS-7 cells (stippled line).B, normalized curve ofA.C, heterologousbinding curves against CCL3
(squares) andCCL5 (triangles). Note thatCCL5hasa lowerKi thanCCL3.D–F, heterologous competitionbindingagainstmetal ionchelator complexes andsingle
complex components (Zn2, chelator) for ZnBip (D), ZnTerp (E), and ZnClTerp (F). Only ZnTerp (E) seems to be slightly able to enhance the binding of CCL4, yet
to maximal levels much lower than what was observed for CCL3 (Fig. 1). For all curves, n 3.
Allosteric Modulation and Agonism in CCR5
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The potency of each of the Terp analogues on CCR5 in com-
plexwithZn2was determined in the IP3 assay described above
(Fig. 4). None of the three Terp analogues gave a significant
effect alone. In complex with Zn2, mTerp exhibited a tend-
ency toward weak agonism at 100 M, pTerp was inactive, and
PhBip showed inverse agonism at 100 M. Thus, the results
strongly support a tridentate complex of Terp with Zn2.
Receptor Mutagenesis—To validate the predicted binding
conformations of ZnBip and ZnTerp, we performed ligand-
mapping experiments with a library comprising 23 receptor
mutants (Fig. 5).We first assessed the cell surface expression of
each mutant by an ELISA technique with antibodies against a
FLAG tag inserted in the N terminus. We then assessed the
ability of the endogenous chemokines CCL3 and CCL5 and the
metal ion chelator complexes ZnBip and ZnTerp to activate
each mutant receptor in an assay measuring IP3 in COS-7 cells
transiently expressing the mutants and the chimeric G protein,
Gqi4myr (Table 1). Finally, homologous competition binding
experiments with 125I-CCL3 were performed (Table 2; for con-
trols and homologous curves, see supplemental Fig. 1). Most of
the mutants showed WT-like cell surface expression, except
F79A, F112A, Y244A, andW248A,which showed absent (F79A
and F112A) or highly reduced (Y244A and W248A) surface
expression (Table 1). Thesemutants were also characterized by
impaired signaling properties. F79A and W248A could not be
activated by any ligand. Y244A could not be activated by CCL3
or CCL5 but could be activated by ZnBip (Table 1), and F112A
showed highly reduced efficacy for all ligands (not shown).
F112A, Y244A, andW248A, but not F79A, bound CCL3, albeit
with reduced Bmax values (Table 2). Thus, F79A is a completely
disintegrated receptor, Ala substitution of Trp-248 results in a
non-signaling receptor, and Y244A selectively impairs
chemokine-induced signaling. The remaining mutants only
selectively impaired the signaling properties of single
ligands, which verifies the general integrity of our mutant
library and allows for validation of the proposed ZnBip and
ZnTerp binding site.
FunctionalMapping of the CCL3 andCCL5Binding Sites—In
addition to the above-mentioned residues important for recep-
tor integrity and chemokine-mediated activation (Phe-79, Phe-
112, Tyr-244, and Trp-248), we found the potency of CCL3 and
CCL5 to be impaired by Y37A in TM-1 and by D276A and
Q277A in TM-7. Interestingly, CCL5 depended to a smaller
degree on Y37A (5.9-fold reduced potency) than CCL3 (15-
fold reduced potency). A potency decrease for CCL5, but not
CCL3, was also observed for E283A andG286F (Table 1). Thus,
through this screen, we identified receptor residues commonly
used by both CCL3 and CCL5 and residues used by each
chemokine distinctly.
Functional Mapping of ZnBip and ZnTerp Binding Sites—
Computationalmodeling suggestedZnBip to interactwithTyr-
108, Phe-109, and Tyr-251 in the major binding pocket and
Tyr-37 and Trp-86 in the minor binding pocket (Fig. 3).
Mutagenesis of aromatic residues in themajor andminor bind-
ing pocket indeed supports this binding mode (Fig. 5, A–C).
Thus, Y251A completely abrogates ZnBip signaling (Fig. 5B),
and Y108A and F109A result in a 3.9- and 3.2-fold decreased
potency, respectively (Fig. 5A). Interestingly, Y108F and Y251F
do not yieldWT-like potency or efficacy (Fig. 5,A and B), high-
lighting a role of the OH groups. This was also suggested from
the computational modeling, where the OH group of Tyr-108
coordinates Zn2, whereas that of Tyr-251 does not directly
interact with ZnBip. Furthermore, W86A in the minor binding
pocket decreased the potency by 9.2-fold, and a minor effect
(2.5-fold) was observed for Y37A, which is rescued by Y37F
(Fig. 5C).
ZnTerp overlaps in its binding site with that of ZnBip and
additionally interacts with Phe-112 and Trp-248 (Fig. 3F). Our
mutagenesis data agree with such a binding pose, because
mutants Y108A, F109A, and Y251A in the major binding
pocket abrogate the activity of ZnTerp (Fig. 5, A and B). Also
here the OH group of Tyr-108, but not that of Tyr-251, is
important for ZnTerp activity, because Y108F does not yield
WT-like potency. W86A results in 50-fold reduced potency
of ZnTerp, and Y37A, although not affecting potency, is crucial
for its efficacy. Interestingly, ZnTerp showed WT-like activity
at Y37F, emphasizing the importance of the aromatic moiety at
this position (Fig. 5C). As discussed above, F112A is character-
ized by low surface expression and reduced efficacies for all
ligands, including ZnBip and ZnTerp. ZnTerp in fact displays
WT-like potency at F112A, and its dependence on Phe-112
therefore could not be confirmed. Furthermore, ZnBip showed
WT-like activity at F112L, highlighting that an aromatic resi-
due in this position is not absolutely required for this ligand.
W248A is a signaling-deficient receptor, and we therefore can-
not draw conclusions regarding its role for ZnTerp (Table 1)
(29).
Finally, Ala mutation of the proposed metal ion anchor Glu-
283 abrogates the activity of ZnTerp in addition to ZnBip, for
TABLE 2
Homologous radioactive competition binding assays for 125I-CCL3
The name and position ofmutants according to the Ballesteros/Weinstein (left) and
Baldwin/Schwartz numbering system are given. KD values are given in log and nM.
Fmut is the factor presenting the -fold decrease of KD for the mutant compared to
WT CCR5. Bmax is given in fmol/100.000 cells. The number of experiments (n) is
given in parentheses.
Allosteric Modulation and Agonism in CCR5
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which this was previously shown (Fig. 5D) (21). The rest of the
mutants showed no or only minor effects (i.e.3-fold; Table 1)
on the potency of ZnBip or ZnTerp and were in fact not sug-
gested as interaction partners from our in silicomodeling. Only
D276A decreased the potency of ZnBip and ZnTerp by 3.3- and
6.1-fold, respectively (Table 1).
Effect of Receptor Mutagenesis on the Allosteric Modulation
by ZnBip and ZnTerp—After having identified and validated
the binding site of ZnBip and ZnTerp, we went on to describe
the structural basis for their allosteric modulation of CCL3
by performing binding studies with 125I-CCL3 on selected
mutants. The metal ion anchor Glu-283 was crucial for the
activity of ZnBip and ZnTerp, whereas F109A selectively
impaired ZnTerp (Fig. 5,A andD). F109A and E283A also abro-
gated the allosteric modulation by ZnBip and ZnTerp (Fig. 6,A
and B). Furthermore, Ala mutation of Trp-248, which was sug-
gested to selectively interact with ZnTerp, nearly abrogated the
CCL3 binding-enhancing ability of ZnTerp but had no effect on
ZnBip (Table 3). Interestingly, the other mutants in the major
binding pocket (Y108A, F112A, and Y251A) had no effect in
binding assays (Table 3), whereas they all affected the agonistic
function of ZnBip and ZnTerp (Fig. 5, A and B, and Table 1).
Finally, we observed a ligand-dependent role of Tyr-37 and
Trp-86. Similar to the functional assays (Fig. 5C), the allosteric
modulation by ZnBip was mainly affected byW86A with a 6.3-
fold decreased Ki compared with WT, but not by Y37A (Fig. 6,
C andD). In contrast, Y37A, but notW86A, impaired the allos-
teric modulation by ZnTerp (Fig. 6, C and D), whereas both
mutants impaired the activity of ZnTerp (Fig. 5C). Altogether,
this highlights a general importance of Phe-109 in the allosteric
modulation by metal ion chelator complexes and a selective
role of Tyr-37 for ZnTerp and of Trp-86 for ZnBip.
FIGURE 3. The active-like CCR5 model and docking poses of ZnBip (green) and ZnTerp (orange). A–C, comparison of the inactive CCR5 crystal structure
(PDB entry 4MBS; light blue) in complexwithmaraviroc (yellow) andour active-like CCR5model (gray) in complexwith ZnBip (green).A, overall structure as seen
from themembrane.B, pocket andextracellular domains as seen from the extracellular side.C,major bindingpocket residues as seen fromTM-5with TM-4 and
-5 removed for clarity.D, receptor-ZnTerpbinding site as seen fromTM-4/-5 tohighlight the shapeof the lower cavity in themajor bindingpocket towhichonly
ZnTerp can reach. This lower cavity is lined by Tyr-108, Phe-109, Phe-112, Trp-248, and Tyr-251. E, comparable view of the receptor-ZnBip binding site. F,
comparison of the Zn2 chelator binding modes using an overlay view.
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Binding Site of the Allosteric Enhancer ZnClTerp—We next
included ZnClTerp, which has a chloro-substituent at the cen-
tral pyridine ring as the only difference from ZnTerp (Fig. 7C)
and which acts as a positive allosteric modulator of CCL3 bind-
ing without agonistic properties (22) (Fig. 7, A and B). Further-
more, it bound allosterically to CCL4, neither enhancing nor
displacing this chemokine (Fig. 2F). Docking reveals that the
chelatormoiety 4-chloro-2,2:6,2-terpyridine (ClTerp) binds
to the same site as Bip and Terp, consisting of Tyr-108, Phe-
109, Phe-112, Trp-248, and Tyr-251 in the major binding
pocket and Tyr-37 and Trp-86 in the minor binding pocket
(Fig. 7D). The chloro-substituent points upward toward the
extracellular surface, where it interacts with Phe-109. In bind-
ing studies with 125I-CCL3, mutations of residues in the major
binding pocket have largely the same effect on ZnClTerp as on
the two other metal ion chelator complexes. Thus, F109A and
E283A abrogated CCL3 enhancement, whereas Tyr-108, Phe-
112, and Tyr-251 play no role or only a minor role (Table 3).
The selective role of minor binding pocket residues that was
observed for ZnBip and ZnTerp is also seen for ZnClTerp,
which, similar to ZnTerp, is only impaired by Y37A (Fig. 8A)
and not by W86A (Table 3). In fact, ZnClTerp was turned into
FIGURE 4. Role of the additional pyridyl ring for ZnTerp. The tridentate
coordination of zinc in ZnTerp allowed by the ortho-position of the nitrogen
atomof the third pyridyl ring is not possible for PhBip,mTerp, or pTerp, which
can thereby not form tridentate complexeswith Zn2. The relevance of these
compounds as CCR5 ligands is compared using the IP3 assay.
FIGURE 5. Receptor mutagenesis in activity assays. The helical wheel diagram of CCR5 in the center shows all residues of the extracellular halves of helices.
The residues thatweremutatedare shown inwhiteonblack;boldface circled residues are conservedamongclassA7TMreceptors. Allmutations included in this
study are listedbeside their respective helices. This figure only presents data for those inboldface type.A–D, activity of ZnBip (left lanes, circles) andZnTerp (right
lanes, squares) at selected receptormutants asmeasured in an IP3 assay. Data arenormalized to themaximal chemokine-induced response at eachmutant (n
3).A, relevantmutations in TM-3of themajor bindingpocket: Y108A/F andF109A.B, relevantmutants in TM-6of themajor bindingpocket: Y251A/F.C, relevant
mutants in the minor binding pocket: Y37A/F and W86A. D, Ala mutation of the metal ion anchor Glu-283 in TM-7.
FIGURE 6. Receptor mutagenesis in heterologous competition binding
assays with 125I-CCL3. The ability of ZnBip (white circle) or ZnTerp (black
square) to enhance the binding of 125I-CCL3 to WT (stippled lines) or four dif-
ferent mutants was assessed in heterologous competition binding experi-
ments. A, E283A; B, F109A; C, Y37A; D, W86A. Data are normalized to the
homologous binding curve (n 3).
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a competitor of 125I-CCL3 at Y37A and, in addition, acted as an
antagonist of CCL5- and ZnBip-mediated activation with
potencies of 0.74 and 0.73 M, respectively (Fig. 8B). CCL3 did
not activate Y37A and therefore was not used as an activating
ligand in the antagonism experiments.
Finally, the binding orientation of ZnClTerp reveals a possi-
ble mechanism for its loss of function. In comparison with
ZnTerp, the overall geometry of the ZnClTerp complex does
not allow favorable aromatic interactions between the major
binding pocket-occupying pyridyl ring and Trp-248 (Fig. 7D), a
residue that is central for the chemokine- (29, 30) and small
molecule-mediated activation of CCR5 (Table 1). In fact, we
observe thatW248Aonly slightly impaired themaximal level of
CCL3 enhancement by ZnClTerp in accordance with the low
surface expression of this mutant receptor. This is in contrast
to ZnTerp, where W248A almost completely abrogated the
enhancement of CCL3 binding (Fig. 9A). The independence of
ZnClTerp from Trp-248 and its deficient interaction with this
residue could thus explain the lack of activity. Ile-116III:16/3.40
has previously been shown to function as a gate for the rota-
tion of Trp-248 during activation of CCR5 (29). We there-
TABLE 3
Heterologous radioactive competition binding assays with 125I-CCL3 as tracer and ZnBip, ZnTerp or ZnClTerp as competitor
Note that the metal ion chelator complexes enhance the binding of 125I-CCL3 and thus do not act as classical competitors. The name and position of mutants according to
the Ballesteros/Weinstein (left) and Baldwin/Schwartz numbering system are given. Ki values are given in log and M. Fmut is the factor presenting the -fold decrease of Ki
for the mutant compared to WT CCR5. ZnClTerp displaces 125I-CCL3 from Y37A. The number of experiments (n) is given in parentheses.
FIGURE 7. Structure, function, and docking of ZnClTerp. A, activity of
ZnClTerp (black triangle) in comparison with ZnTerp (stippled line) at CCR5
as measured in an IP3 assay (see “Experimental Procedures” for details).
Data are normalized to maximal response induced by chemokine at WT
(n  3). B, ability of ZnClTerp (black triangle) in comparison with ZnTerp
(stippled line) to enhance the binding of 125I-CCL3 to CCR5 as determined
in a heterologous competition binding assay. Data are normalized to the
homologous binding curve (n 3). C, structure of ZnClTerp. D, docking of
ZnClTerp (cyan) in comparison with ZnTerp (orange) to the active-like
CCR5model, including residues in the vicinity of the chloro-substituent of
ZnClTerp.
FIGURE 8. The effect of mutation Y37A on the allosteric action and activ-
ity of ZnClTerp. A, heterologous competition binding of 125I-CCL3 to Y37A
competed by ZnClTerp (triangle) in comparison with ZnTerp (square). Data
are normalized to the homologous binding curve (n  3). B, ZnClTerp can
antagonize ZnBip-induced (black triangle) and CCL5-induced (white triangle)
activity of Y37A, asmeasured in an IP3 assay. Data are normalized tomaximal
response induced by chemokine or ZnBip at Y37A (n 3).
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fore tested whether ZnClTerp could be turned into an ago-
nist if this gate were removed. Indeed, at I116A, ZnClTerp
gained activity and 2.9-fold higher potency than ZnTerp at
WT CCR5 (Fig. 9B).
Discussion
We herein describe the structural basis for CCR5 activation
by small molecule agonists, the metal ion chelator complexes
ZnBip, ZnTerp, and ZnClTerp. ZnTerp has a higher potency
than ZnBip due to its deeper anchorage in the major binding
pocket, whereas ZnClTerp lacks intrinsic activity, presumably
due to an altered positioning in this pocket. The allosteric
enhancement of CCL3 by all three ligands arises from a positive
modulation of an allosteric interface between the chelator and
chemokine binding sites comprising Phe-109 in TM-3 and aro-
matic residues in theminor binding pocket.Metal ion site engi-
neering has been used for decades to predict helical connectiv-
ity, initially described in the tachykinin receptorsNK1 andNK3
(31–33) and followed up by various receptors (34–36), hereun-
der the two CXC-chemokine receptors ORF74 encoded by
human herpesvirus 8 (HHV8) (37, 38) and CXCR3 (39). In con-
trast to the above-mentioned chemokine receptors, the metal
ion chelator complex site in CCR5 is not engineered but rather
naturally occurring (21).
CCR5 Activation Mechanism and Activity Profile of ZnBip,
ZnTerp, and ZnClTerp—The activation of 7TM receptors is
controlled by a number of conserved residues that constitute
microswitches and change rotameric state or interaction part-
ners upon receptor activation and thereby transduce an extra-
cellular signal into an intracellular response. The most impor-
tantmicroswitches are 1) an arginine at position III:26/3.50 that
is part of the DRY motif and interacts with the adjacent
AspIII:25/3.49 in the inactive conformation or TyrV:24/5.58 in the
active conformation; 2) TyrVII:20/7.53 of the NPXXY motif in
TM-7, which interacts with aromatic residues in the intracellu-
lar small helix 8 or in the receptor core in the inactive and active
conformation, respectively; and 3) the so-called toggle switch
TrpVI:13/6.48 of the CWXP motif in TM-6 (30, 40, 41). Upon
receptor activation, this tryptophan is suggested to rotate
toward TM-5 (30, 40, 41), which allows for an outward move-
ment of TM-6 on the intracellular side, a conformational
change that indeed was observed in active-like crystal struc-
tures of the 2-adrenergic receptor and US28 (8, 42, 43). How-
ever, a rotation of TrpVI:13/6.48 was not observed in these struc-
tures, and in fact TrpVI:13/6.48 is only conserved in 71% of all
7TM receptors. Thus, whereas the movement of TM-6 upon
receptor activation is by now generally accepted, the role of
TrpVI:13/6.48 seems to be more subtle and less universal.
For CCR5, we have previously shown that CCL3- and CCL5-
mediated activation depends on TrpVI:13/6.48, which is Trp-248
(29, 30). Here we find that also small molecule-mediated acti-
vation depends on Trp-248, which allows us to propose a cen-
tral role of Trp-248 for the activation mechanism of CCR5.
Furthermore, Steen et al. (29, 30) showed that the rotamer
switch of Trp-248 is linked to a slight movement of Tyr-
244VI:09/6.44 located one helical turn below, which in turn is
controlled by Ile-116 in TM-3 on the opposite site of the major
binding pocket. Consistent with this, Tan et al. (13) described
Trp-248 together with Tyr-244 as relays of receptor activation
in their crystal structure of CCR5. We suggest that the interac-
tion of ZnTerp with Trp-248 accounts for its higher potency
compared with ZnBip, which does not directly interact with
Trp-248 yet still acts as agonist. ZnClTerp interacts in an
impaired manner with Trp-248 (Fig. 7D), and its lack of activa-
tion could be due to its inability to induce a correct stabilization
of this residue, therefore hindering the conformational change
of Trp-248 required for receptor activation. This is confirmed
by the observation that ZnClTerp gains activity at I116A (i.e.
when the gating function of Tyr-244 and Trp-248 is released).
An Allosteric Interface between CCL3 and the Metal Ion
Chelator Complex Binding Site—According to the two-step
model of chemokine-mediated receptor activation (9, 10), the
chemokine core and extracellular receptor domains mediate
binding of chemokines to their receptors. For CCL3, this
involves the receptor N terminus and residues in ECL-2
(including Arg-168) and ECL-3 but also residues at the top of
TM-5 and -6 (reviewed in Refs. 9 and 10). A TXPmotif in TM-2
and the surrounding non-polar residues play a role for the sec-
ond activity-inducing step (44, 45). Govaerts et al. (44) showed
that a serine, cysteine, or threonine two residues before the
conserved proline in TM-2 fortifies the proline-induced kink
via a hydrogen bond from their side chain to the main chain in
the turn below. They also found that an entire hydrophobic
network around the TXP motif, among others comprising res-
idues Phe-85II:19/2.58, Leu-104III:04/3.28, Phe-109III:09/3.33, and
Phe-112III:12/3.36, is important for CCL3-mediated receptor
activation (46). We previously showed the importance of Asp-
276 for CCL3-mediated activation (21) and in the present study
extend this observation to Tyr-37 and Gln-277.
We identify the metal ion chelator binding sites in CCR5 as
consisting of Tyr-37, Trp-86 (minor binding pocket), Arg-168
(ECL-2a), Tyr-108, Phe-109, and Tyr-251 (major binding
pocket) and, for ZnTerp and ZnClTerp, additionally Phe-112
and Trp-248 (lower cavity of the major binding pocket). Thus,
this site lies directly beneath the CCL3 binding site in CCR5,
and both ligand types interact with some of the same residues,
such as Tyr-37, Phe-109, andArg-168.We therefore identify an
allosteric interface located on the verge of the CCL3 and metal
ion chelator complex binding sites.Whereasmetal ion chelator
FIGURE 9. Interactions in the major binding pocket determine activity
profiles of ZnTerp and ZnClTerp. A, heterologous competition binding of
125I-CCL3 to W248A competed by ZnTerp (squares) and ZnClTerp (triangles).
Data are normalized to themaximal effect observed for the ligandonWT (n
3). B, activity of ZnClTerp (triangle) in comparison with ZnTerp (stippled line)
on I116A as measured in an IP3 assay (see “Experimental Procedures” for
details). Data are normalized to maximal response induced by chemokine at
I116A (n 3).
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complexes approach this allosteric interface from their trans-
membrane receptor domain, CCL3 approaches it from the
extracellular side (Fig. 10). Changing the receptor at this allos-
teric interface alters the direction and nature of the allosteric
interaction. Thus, F109A abrogates the positive allosteric char-
acter and leaves the metal ion chelator complexes as pure ago-
nists with no effect on CCL3 binding. Y37A even turns
ZnClTerp into a competitive displacer and an antagonist and
induces an inactive receptor conformation, withwhich the ago-
nist CCL3 has an inherently low affinity. Arg-168, also part of
both the chemokine andmetal ion chelator site, is in our active-
like model rotated downward to the metal ion chelator ligand,
whereas it points outward into the extracellular space in the
antagonist-bound CCR5 crystal structure (13).
Ligand-directed Biased Action of Small Molecules in CCR5, a
Model for Future BiasedDrugs—It should also be noted that any
allosteric interface is ligand-specific and depends on the bind-
ing site and induced receptor conformations for both the
endogenous ligand and the allosteric modulator. This is high-
lighted by the finding that ZnBip, ZnTerp, and ZnClTerp are
differently influenced by alterations in the minor binding
pocket (Y37A and W86A; Figs. 5C and 8 and Tables 1 and 3).
The situation is also entirely different for CCL5, which is not
enhanced in its binding by metal ion chelator complexes and
interacts differently with CCR5 than CCL3 (21). For example,
only CCL5 directly interacts with the metal ion anchor residue
Glu-283VII:06/7.39. A glutamate in position VII:06/7.39 is found
in 74% of chemokine receptors, and because it is involved in the
binding of most current chemokine receptor antagonists (14),
position VII:06/7.39 might give rise to an overlap with the
chemokine site (9). In addition to CCL5, this was, for example,
shown for the interaction of CCL2 with CCR2 (47) and other
CC-chemokine receptors (reviewed in Ref. 9). Furthermore, we
find CCL5 to have a lower dependence on Tyr-37 than CCL3.
We propose Tyr-37 to be part of the allosteric interface
between metal ion chelator complexes and CCL3, and a differ-
ent interaction ofCCL5withTyr-37might thus explain the lack
of positive allosteric enhancement of this chemokine by metal
ion chelator complexes.
A third chemokine interacting with CCR5 is CCL4. CCL4 is
known to bind to the receptor N terminus and ECL-2, and also
residues within the transmembrane receptor domain contrib-
ute to CCL4 binding, including Tyr-37, Tyr-108, Asp-276, Glu-
283, and Met-287 (reviewed in Ref. 9). Tyr-37 and Tyr-108 are
part of the allosteric interface proposed for CCL3 andmetal ion
chelator complexes and might be utilized similarly by CCL4
and ZnTerp for allosteric enhancement. A dual interaction
with Glu-283 does, however, favor a competitive binding
behavior toward CCL4, which might explain the absent (for
ZnBip and ZnClTerp) and low level of positive allosteric
enhancement (for ZnTerp) observed for CCL4. Rational design
of allosteric modulators in general requires detailed insights
into the interaction of each chemokine with its receptor(s) but
FIGURE10.Allosteric interfacebetweensmallmoleculeandchemokinebindingsites.A, schematicdrawingof receptor (TM-1 to -5);B, theextracellular half
of our CCR5 model. The parts of CCR5 that were shown to bind CCL3 are presented in light blue, and parts of CCR5 involved in CCL3-mediated activation are
shown in dark blue and include the TXP motif in TM-2. The approximate small molecule binding site in CCR5 is shown in yellow. The border between the
chemokine and small molecule site forms the allosteric interface (green). The hydrophobic core of CCR5 that confers receptor integrity and is essential for the
receptor activation mechanism is shown in red.
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at the same time will allow us to manipulate those interactions
for singular chemokine-receptor pairings.
A Hydrophobic Core in CCR5 Maintains Receptor Integrity
and Relays Signal Transduction—In addition to their central
role for CCR5 activation, Tyr-244 and Trp-248 are also impor-
tant for receptor integrity, as illustrated by the low surface
expression of Y244A and W248A (Table 1). We mutated the
entire set of aromatic residues in the main binding pocket of
CCR5 and identified two additional residues with importance
for receptor activation and integrity: Phe-79 and Phe-112
(Table 1). F79A could not be detected at the cell surface andwas
not activated by any ligand; nor could it bind CCL3. Also,
F112A displayed very low surface expression and similarly low-
ered efficacies and Bmax for CCL3. Interestingly, both residues
are located deeply in themain binding crevice, at the same level
as Tyr-244 and Trp-248. Thus, Phe-79 is located centrally in
TM-2 two helical turns below Trp-86 and directly underneath
Tyr-108 in TM-3. Phe-112 is located in TM-3 and points
directly toward Trp-248. The model shows that Phe-79, Phe-
112, Tyr-244, andTrp-248 pack tightly and form a hydrophobic
core at the center of the receptor and the base of the transmem-
brane binding pocket (Fig. 10). We find this hydrophobic core
to be important for maintaining structural receptor integrity.
Its deep location at the bottom of the transmembrane binding
pocket also suggests a role in relaying signal transduction. This
was proven for Tyr-244 and Trp-248 (13, 29, 30), and we now
identify Phe-79 in TM-2 as central for transducing activation
signals in the minor binding pocket.
Antagonism in CCR5—Like the majority of small molecule
ligands for chemokine receptors (14), maraviroc is positively
charged and engages in a salt bridge with the chemokine recep-
tor-conserved Glu-283. It furthermore interacts with Tyr-37,
Thr-195, and Thr-259, and its phenyl ring reaches deeply into
the major binding pocket interacting with Tyr-108, Phe-109,
Phe-112, Trp-248, andTyr-251 (13). Therefore, the binding site
of maraviroc and the metal ion chelator complexes identified
here overlap. However, maraviroc differently influences the
allosteric interface, as indicated by the different rotation ofArg-
168 (pointing outward) and its opposite property (being an
antagonist). Other smallmolecule CCR5 antagonists (e.g.TAK-
779, aplaviroc, SCH-C, vicriviroc, and YM-370749) also bind
across both subpockets (major and minor) and interact with
Glu-283 (48–50). Two of them, TAK-779 and aplaviroc, were
also suggested to directly interact with Trp-248 (48, 49). Fur-
thermore, the antagonist aplaviroc makes extensive interac-
tions with ECL-2b (i.e. the part downstream of the disulfide
bridge) (21), whereas our agonists or allostericmodulators here
interact with ECL-2a. Together, this highlights how different
ligands can fit the same overall transmembrane binding pocket
yet have distinct allosteric interfaces and provoke different out-
comes: inhibition, activation, and allosteric modulation. This
outcome also depends on the applied chemokine. Aplaviroc, for
example, can fully inhibit CCL3- and CCL5-mediated activa-
tion as a result of its antagonistic activity and ability to stabilize
an inactive receptor conformation.However,whereas aplaviroc
also fully displaces CCL3, it cannot fully overcome CCL5 bind-
ing (15, 51). This reflects the different binding modes of these
chemokines to CCR5, which differ, among others, in terms of
utilizing receptor residues Tyr-37 and Glu-283 (Table 1). Fur-
thermore, the receptor N terminus and ECL-2 are the domains
contributing most strongly to chemokine affinity, and it is not
surprising that a small molecule antagonist binding to the
transmembrane receptor domain cannot sterically compete
with binding to these regions. These insights illustrate that
small molecule drugs can be tailored to modify the interactions
of specific chemokine-receptor pairs, a concept that holds
much promise because it allows us to achieve a currently unex-
ploited level of control over the chemokine system.
The current lack of success in producing clinically efficacious
anti-inflammatory drugs targeting chemokine receptors (4, 17,
52) remains as a reminder that we have not yet fully understood
the complexity of the chemokine system. In contrast to the
previous view of this system as being redundant, it now seems
that it is finely tuned and displays ligand, receptor, and tissue
bias (2–4). It is also evident that the interaction between
chemokines and receptors is better described by a “pseudo”-
two-step mechanism consisting of multiple steps (10). The
present study describes themolecular basis forCCR5 activation
and the complexity of allosteric interactions in chemokine
receptors. This knowledge is central for future rational design
of specific ligand types, such as allosteric or overlapping antag-
onists, biased ligands, or modulators of chemokine function.
Experimental Procedures
Materials—Human CCL3 was purchased from Peprotech.
125I-CCL3 was produced in house. ZnCl2, Bip, Terp, ClTerp,
and DMSO were purchased from Sigma-Aldrich and used
without further purification. Synthesis of PhBip was performed
as described previously (27), as was the intermediate for
both 2,2:6,3-terpyridine (mTerp) and 2,2:6,4-terpyridine
(pTerp). Both mTerp and pTerp were synthesized following a
procedure published previously (25). The structure for all syn-
thesized compounds was confirmed by 1H and 13C NMR and
high resolutionmass spectrometry. The highest concentrations
of metal ion chelator complexes were 20 mM for ZnBip and 2
mM for ZnTerp/ZnClTerp and were made from 0.2 or 0.02 M
ZnCl2 in water and 100 mM Bip or 10 mM Terp/ClTerp in
DMSO, respectively, and were supplemented with water and
70% ethanol. The ratio of Zn2/chelator was 1:2 to ensure full
complexation of Zn2. Dilutions were made in water. CCR5
was cloned in-house from a leukocyte DNA library. The pro-
miscuous G protein Gqi4myr was kindly provided by Evi Koste-
nis (University of Bonn). Myo[3H]inositol (PT6-271), iodine-
125, and 125I-CCL4 were purchased from PerkinElmer Life
Sciences.
Molecular Biology—Receptor mutations were introduced by
the PCR overlap extension technique or the QuikChange tech-
nique (Agilent Technologies) using WT CCR5. All reactions
were carried out using Pfu polymerase (Stratagene) under con-
ditions recommended by the manufacturer. The mutations
were cloned into pcDNA3.1 for use in IP3 and binding assays
(Invitrogen) or into pcDNA3.1 with M1 tag for ELISA. All
constructs were verified by restriction endonuclease digestion
and DNA sequencing (GATC Biotech).
Computational Modeling and Ligand Docking—A CCR5
model was generated using the recently crystallized active-like
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structure of US28 in complex with its partial inverse agonist
CX3CL1 (PDB entry 4XT1) (8). 50models were generated using
MODELLER version 9.14 (53), and the five best models were
chosen for subsequent docking experiments, based on the
MODELLER objective function (DOPE), the GA341 score, and
the overall orientation of conserved residues in the binding
pocket of the models. The N and C termini of CCR5 were not
considered during model generation, whereas the structural
waters of US28 were preserved. Model refinement was per-
formed in Vega ZZ version 3.1 (54) through 500 steps of conju-
gate gradient (CG) minimization in the SP4 force field while
keeping the protein backbone fixed. The overall quality of the
refined models was valuated using PROCHECK, ERRAT, and
Verify 3D. All docking experiments were performed in AutoD-
ock version 4.2.6 (55), using a force field adjusted formetal ions
(56). Docking was carried out on the five best-scoring models,
usingmanuallyconstrainedZn2-containingreceptors, generated
as follows. Zn2was placed in the vicinity ofGlu-2837.39/VII:06 and
relaxed in the binding site through 500 steps of CG in the SP4
force field, followed by 1000 CG steps of binding site optimiza-
tion within a 10-Å radius of Zn2. Default parameters for the
flexible ligand GA-LS docking were employed for all docking
experiments, using a 46	 46	 46-Å3 docking grid centered on
Zn2. 50 runs of GA-LS were performed for each ligand/recep-
tor model pair. Results were clustered, and the lowest energy
cluster representatives were chosen for further analyses. The
binding sites of the best scoring ligand/receptor pairs were sub-
sequently minimized through 500 steps of CG minimization
using the SP4 force field, while keeping the protein backbone
fixed, and further globally optimized through 500 steps of
Monte Carlo simulation, as implemented in ICM version 3.8
(Molsoft LLC, San Diego, CA).
Transfection and Tissue Culture—COS-7 cells were grown in
DMEM with Glutamax (Invitrogen) supplemented with 10%
FBS, 180 units/ml penicillin, and 45 g/ml streptomycin at
37 °C in a 10% CO2, 90% air-humidified atmosphere. Transfec-
tion of cells was carried out by the calcium phosphate precipi-
tationmethod (57, 58). Briefly, plasmidDNA (20g of receptor
cDNA and 30 g of Gqi4myr for IP3 assays or 40 g of receptor
cDNA for 125I-CCL3-binding assays) wasmixed with TE buffer
(10 mM Tris-HCl, 2 mM EDTA-Na2, pH 7.5) and 30 l of cal-
cium chloride (2 M) to a total volume of 480 l and was then
added to the same amount of HEPES-buffered saline (280 mM
NaCl, 50 mM HEPES, 1.5 mM Na2HPO4, pH 7.2). The mixture
was allowed to precipitate for 45 min at room temperature,
after which the precipitate and 300l of chloroquine (2mg/ml)
in 10 ml of culture medium was added to the 6 	 106 COS-7
cells seeded the day before. Transfection was stopped after 5 h
by replacing with fresh medium, and cells were incubated
overnight.
ELISA—Cells were transfected with M1-tagged WT or
mutant receptors as described above. The following day, 35,000
cells/well were seeded in 96-well plates, which 24 h later were
washed in Tris-buffered saline (TBS; 0.05 M Tris base, 0.9%
NaCl, pH 7.6), fixed in 3.7% formaldehyde for 15 min at room
temperature, washed three times in TBS, and incubated in TBS
with 2% BSA for 30 min. The cells were then incubated for 2 h
with anti-FLAG M1-antibody (Sigma-Aldrich) at 2 g/ml in
TBSwith 1mMCaCl2 and 1%BSA.After threewasheswithTBS
supplemented with 1 mM CaCl2, the cells were incubated
with goat anti-mouse HRP-conjugated antibody at 0.8 g/ml
(Thermo Fisher Scientific) for 1 h. After three additional
washes, the immunoreactivity was revealed by the addition of
TMB Plus substrate (Kem-En-Tec Diagnostics, Taastrup, Den-
mark). The reaction was stopped with 0.2 M H2SO4 after 5
min. Absorbancewasmeasured at 450 nmon aWallac Envision
2104 Multilabel Reader (PerkinElmer Life Sciences).
Functional Scintillation Proximity IP3 Assay (SPA)—One day
after transfection, COS-7 cells (35,000 cells/well) were incu-
bated with myo-[3H]inositol (5 l/ml, 2 Ci/ml) in 0.1 ml of
medium overnight in a 96-well plate. The following day, cells
were washed twice in PBS and were incubated in 0.1 ml of
Hanks’ balanced salt solution (Invitrogen) supplemented with
10mMLiCl at 37 °C in the presence of various concentrations of
ligands for 90 min. Assay medium was then removed, and cells
were extracted by the addition of 50 l of 10 mM formic acid to
each well, followed by incubation on ice for 30–60 min. The
[3H]inositol phosphates in the formic acid cell lysates were
thereafter quantified by adding yttrium silicate-poly-D-Lys-
coated SPA beads. Briefly, 35 l of cell extract was mixed with
80 l of SPA bead suspension in H2O (12.5 g/l) in a white
96-well plate. Plates were sealed, agitated for at least 30 min,
and centrifuged for 5 min at 402 relative centrifugal force. SPA
beads were allowed to settle and react with the extract for at
least 8 h before radioactivity was determined using a Packard
TopCountNXTTM scintillation counter (PerkinElmer Life Sci-
ences). All determinations weremade in duplicate. Normalized
and averaged curves of at least three experiments are shown in
the figures. Unless otherwise stated, 100% accounts for the
maximal chemokine-induced response observed at the given
mutant, or WT when chemokines were inactive at the mutant,
and 0% is the signaling of the given receptor (mutant orWT) in
the absence of any ligand. These overall readouts have previ-
ously been used effectively for CCR5, CXCR4, and other
chemokine receptors (21, 22, 59, 60).
cAMP Turnover Assay—CHO cells stably transfected with
CCR5WT or naive CHO cells were grown in HAMF12 supple-
mented with 10% FBS, 180 units/ml penicillin, 45 g/ml strep-
tomycin, and 0.5 mg/ml gentamicin at 37 °C in a 5% CO2, 90%
air-humidified atmosphere. The HitHunter cAMP assay for
small molecules (DiscoveRx) was used. Briefly, 35,000 cells
were seeded in 96-well plates in 0.1 ml of cell culture medium.
The following day, cells were washed once in 200 l of Hepes-
buffered saline, and 94 l of Hepes-buffered saline supple-
mented with 1 mM isobutylmethylxanthine was added. After a
30-min incubation at 37 °C, 1l of forksolinwas added to a final
concentration of 10M, and cells were further incubated for 15
min at 37 °C. Then 5 l of ligands were added. Following a
30-min incubation at 37 °C, the buffer was aspirated, cells were
washed once in 100l of prewarmedPBS, and 30l of PBSwere
added. The procedure was then followed according to theman-
ufacturer’s instructions (i.e. by the addition of 15l of antibody
solution, 60 l of cAMP Working Detection Solution, incuba-
tion at room temperature for 60 min, and the addition of 60 l
of cAMP Solution A). Plates were agitated lightly at room tem-
perature for 60min, and luminescencewasmeasured on aWal-
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lac Envision 2104 Multilabel Reader (PerkinElmer Life Science
Products).
Ca2 Release Assay—CHO cells stably transfected with
CCR5 WT or naive CHO cells were grown under the same
conditions as for the cAMP turnover assay. For an experiment,
cells were seeded on an 8-well NuncTMLab-TekTMChambered
Coverglass (Thermo Scientific) and grown until 80% conflu-
ence. Cells were washed once with 200 l of wash buffer pre-
warmed to 37 °C (Hanks’ balanced salt solution (Gibco,
Thermo Fisher Scientific) supplemented with 20 mM HEPES
(Invitrogen), 1 mMCaCl2, 1 mMMgCl2, and 0.7mg/l probeni-
cid (Life Technologies, Thermo Fisher Scientific)). Subse-
quently, 200 l/well of prewarmed loading buffer (wash buffer
supplemented with 0.2% Fluo-4 (Life Technologies, Thermo
Fisher Scientific)) were added. Cells were incubated for 30 min
at 37 °C in 5% CO2 in the dark. After incubation, cells were
washed twicewith 200l of prewarmedwash buffer, and 150l
of 37 °C prewarmed cell medium was added. The cells were
treated with CCL3 (0.1M), CCL5 (0.1M), ZnBip (1mM), zinc
(1 mM), or Bip (1 mM) and respective buffer controls. Changes
in calcium concentrations were recorded with a Zeiss LSM 780
confocal microscope recording with 1 frame/s at 488 nm exci-
tation. Ligands were added after the fluorescence signal
reached a baseline and was stable.
Iodination of CCL3—17 g (2 nmol) of carrier-free CCL3
(R&D Systems, Bio-Techne Corp.) were dissolved in 10 l of
iodination buffer (300 mM phosphate buffer, pH 7.4). 4 l of
iodine-125 (PerkinElmer Life Sciences, NEX033A) were added.
For the reaction, 6	 5l of a 3g/ml chloramine T solution in
300 mM phosphate buffer, pH 7.4, were added while occasion-
ally stirring and at 1-min intervals. After 6min, the reactionwas
stopped by the addition of 400 l of water with 0.1% trifluoro-
acetic acid. The reaction mixture was then purified on a C18
column with an acetonitrile gradient from 20 to 80% over45
min.
125I-CCL3 and 125I-CCL4 Competition Binding Assays—6	
106 COS-7 cells were transfected with 40 g of receptor cDNA
and transferred to culture plates 1 day after transfection. The
number of cells seeded perwell was determined by the apparent
expression efficiency of the receptors and was aimed at obtain-
ing 5–10% specific binding of tracer. The number of cells thus
ranged from 10,000 to 300,000. Two days after transfection,
cells were assayed by competition binding for 3 h at 4 °C using
10–15 pM 125I-CCL3 or 125I-CCL4 plus unlabeled ligand in 0.2
ml (24-well plates) or 0.3 ml (12-well plates) of 50 mM Hepes
buffer, pH 7.4, supplemented with 1 mM CaCl2, 5 mM MgCl2,
and 0.5% (w/v) bovine serum albumin. After incubation, cells
werewashed quickly two timeswith 4 °C binding buffer supple-
mented with 500 mM NaCl. Nonspecific binding was deter-
mined in the presence of 0.1 M unlabeled CCL3 or CCL4,
respectively. Determinations were made in duplicate.
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